Developer docs
API playgroundTry for free, no card

Search company profiles

Vedanta Biosciences

Full company profile

uuid000097y

Namestring
Vedanta Biosciences
Legal namestring
Vedanta Biosciences, Inc.
Websiteurl
vedantabio.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Vedanta Biosciences is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing Live Biotherapeutic Products (LBPs) composed of defined bacterial consortia for serious gastrointestinal diseases. The company's lead asset, VE303, is an orally administered eight-strain consortium of live commensal bacteria currently in a pivotal Phase 3 trial (RESTORATiVE303) for prevention of recurrent Clostridioides difficile infection (CDI). The pipeline additionally includes VE202, a 16-strain consortium for ulcerative colitis (Phase 2 did not meet primary endpoint in August 2025), and VE707, a preclinical program targeting Gram-negative antimicrobial-resistant infections with IND submission planned for the first half of 2026.

The company's proprietary Product Engine spans a strain library of approximately 100,000 bacterial isolates drawn from four continents, computational consortium design tools, and in-house CGMP manufacturing capabilities covering 75 bacterial species. Vedanta holds an exclusive license to the foundational Honda patents covering Clostridium clusters IV and XIVa from the University of Tokyo, with an IP estate exceeding 80 issued patents and pending applications extending coverage to 2043. The European Patent Office fully upheld three core Honda patents in 2023.

Vedanta's business model is standard for late clinical-stage biopharma: pre-revenue with no approved products, generating economic value through eventual pharmaceutical product sales contingent on regulatory approval. Revenue is supplemented by substantial non-dilutive government funding, including a BARDA contract of up to $114.2 million for VE303 development and CARB-X grants of approximately $16.6 million. The company employs 101-250 staff, is privately held with institutional and strategic backers including Magnetar Capital, Pfizer, AMR Action Fund, and AXA Investment Managers, and is preparing commercial infrastructure under a newly appointed Head of Commercial.

Short descriptiontext

Vedanta Biosciences is a clinical-stage biopharmaceutical company developing orally administered defined bacterial consortia (Live Biotherapeutic Products) for serious gastrointestinal diseases, with lead asset VE303 in pivotal Phase 3 for recurrent C. difficile infection.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome therapeutics, live biotherapeutic products, bacterial consortia therapy, gastrointestinal disease drugs, biologics manufacturing
Industry3 codes
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYHLAAAFAC
Consortia & Defined Microbial Community Therapeutics
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Microbiome Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Developing Live Biotherapeutic Products (LBPs) for gastrointestinal diseases. VE303 is in Phase 3 registrational trial for prevention of recurrent C. difficile infection. Potential future revenue from pharmaceutical product sales upon regulatory approval.

vedantabio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vedanta Biosciences develops and manufactures oral Live Biotherapeutic Products (LBPs) consisting of rationally designed defined bacterial consortia to treat gastrointestinal diseases. Its lead candidate VE303 is an eight-strain commensal bacterial consortium in pivotal Phase 3 development for the prevention of recurrent C. difficile infection. The company also develops VE202 for ulcerative colitis and VE707 for Gram-negative antimicrobial-resistant infections, supported by a proprietary product engine and in-house CGMP manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • VE303 reduced CDI recurrence rate to 13.8% vs 45.5% for placebo (31.7% absolute risk reduction, >80% reduction in odds of recurrence) in Phase 2 CONSORTiUM study
+4 more records
Product overview1 text field

Vedanta Biosciences is developing a portfolio of defined bacterial consortia as oral Live Biotherapeutic Products (LBPs) for gastrointestinal diseases. The company's lead product is VE303, an eight-strain defined bacterial consortium in pivotal Phase 3 for prevention of recurrent C. difficile infection. VE202 (16-strain consortium for ulcerative colitis) completed Phase 2 but did not meet primary endpoint. VE707 is a preclinical program for Gram-negative AMR infections. The company's proprietary Product Engine platform enables rational selection and manufacturing of defined bacterial consortia from pure clonal cell banks, supported by in-house CGMP manufacturing capabilities.

Product and service4 records
1VE303
CategoryLive Biotherapeutic Product (LBP)
Description

VE303 is an orally-administered defined bacterial consortium candidate consisting of eight strains of live commensal bacteria developed for the prevention of recurrent C. difficile infection (rCDI). It is manufactured from pure clonal cell banks yielding a standardized pharmaceutical composition that bypasses the need for donor fecal material. VE303 is currently in pivotal Phase 3 (RESTORATiVE303) and holds FDA Orphan Drug and Fast Track designations.

2VE202
CategoryLive Biotherapeutic Product (LBP)
Description

VE202 is a defined bacterial consortium of 16 non-pathogenic, non-toxigenic Clostridia strains developed as an oral therapy for inflammatory bowel disease, specifically mild-to-moderate ulcerative colitis. The Phase 2 COLLECTiVE202 study did not meet its primary endpoint in August 2025.

3VE707
CategoryLive Biotherapeutic Product (LBP)
Description

VE707 is a preclinical defined bacterial consortium candidate designed to prevent Gram-negative antimicrobial-resistant (AMR) infections, including carbapenem-resistant and ESBL-producing Klebsiella pneumoniae and Escherichia coli, by reducing gut colonization with multidrug-resistant organisms in high-risk populations. IND submission is planned for 1H 2026.

4Product Engine
CategoryMicrobiome Discovery Platform
Description

The Product Engine is Vedanta's proprietary discovery platform integrating one of the world's largest libraries of gut bacteria strains (nearly 100,000 isolates from hundreds of individuals across four continents), vast clinical datasets, proprietary computational consortium design tools, co-culture systems, and animal models. It supports rational selection and development of defined bacterial consortia as Live Biotherapeutic Products.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1University of Tokyo
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Honda patents are exclusively licensed to Vedanta from the University of Tokyo. These fundamental patents cover compositions and therapeutic uses of clostridial bacteria derived from the human microbiome. Dr. Kenya Honda, inventor, is a scientific co-founder of Vedanta.

vedantabio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed Vowst (SER-109), the first FDA-approved oral microbiome therapeutic for recurrent C. difficile infection. Directly comparable as a defined-consortium LBP competitor pursuing the same rCDI indication with an oral spore-based product.

TypeDirect peer
Description

Markets Rebyota (fecal microbiota, live-jslm), the first FDA-approved microbiome therapy for rCDI. Direct competitor in the recurrent CDI space, though Rebyota is rectally administered rather than oral.

TypeDirect peer
Description

Developed CP101, an oral microbiome therapeutic for recurrent C. difficile infection. Directly comparable microbiome platform pursuing the same rCDI indication, though Finch has scaled back operations.

TypeDirect peer
Description

Clinical-stage biotech developing microbiome-based therapies for serious diseases, including CDI and inflammatory conditions. Comparable as a platform LBP company with multiple defined-consortium programs.

TypeDirect peer
Description

European clinical-stage company developing microbiome-based therapies (MaaT013, MaaT033) for GI diseases including CDI and acute Graft-versus-Host Disease. Direct microbiome peer operating in the same indication space.

6Second Genome
TypeEmerging player
Description

Clinical-stage biotech identifying microbiome-derived therapeutics for GI and metabolic diseases. Comparable microbiome discovery platform, though focused more on small-molecule drugs derived from microbiome insights than whole-consortium LBPs.

TypeDirect peer
Description

Pioneer in standardized FMT-based therapeutics, acquired by Ferring. Developed Rebyota, the first FDA-approved microbiome product, making it the closest historical comparator to Vedanta's LBP approach.

84D pharma
TypeDirect peer
Description

UK-based clinical-stage microbiome therapeutics company developing single-strain and defined-consortium LBPs (e.g., Blautix for IBS). Comparable as a live biotherapeutic platform pursuing GI indications.

TypeEmerging player
Description

Developer of engineered phage-based microbiome medicines (Eligobiotics). Comparable as a microbiome-focused therapeutics platform, though uses a different modality (phage-delivered payloads rather than whole consortia).

TypeBroad incumbent
Description

Major pharmaceutical investor in Vedanta with a broad infectious disease and CDI portfolio (historically Dificid). Comparable as a strategic counterparty and potential acquirer with overlapping interest in the rCDI market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors43 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vedanta Biosciences

Microbiome Therapeuticsvedantabio.com

Vedanta Biosciences is a clinical-stage biopharmaceutical company developing orally administered defined bacterial consortia (Live Biotherapeutic Products) for serious gastrointestinal diseases, with lead asset VE303 in pivotal Phase 3 for recurrent C. difficile infection.

What Vedanta Biosciences does

Vedanta Biosciences is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing Live Biotherapeutic Products (LBPs) composed of defined bacterial consortia for serious gastrointestinal diseases. The company's lead asset, VE303, is an orally administered eight-strain consortium of live commensal bacteria currently in a pivotal Phase 3 trial (RESTORATiVE303) for prevention of recurrent Clostridioides difficile infection (CDI). The pipeline additionally includes VE202, a 16-strain consortium for ulcerative colitis (Phase 2 did not meet primary endpoint in August 2025), and VE707, a preclinical program targeting Gram-negative antimicrobial-resistant infections with IND submission planned for the first half of 2026.

The company's proprietary Product Engine spans a strain library of approximately 100,000 bacterial isolates drawn from four continents, computational consortium design tools, and in-house CGMP manufacturing capabilities covering 75 bacterial species. Vedanta holds an exclusive license to the foundational Honda patents covering Clostridium clusters IV and XIVa from the University of Tokyo, with an IP estate exceeding 80 issued patents and pending applications extending coverage to 2043. The European Patent Office fully upheld three core Honda patents in 2023.

Vedanta's business model is standard for late clinical-stage biopharma: pre-revenue with no approved products, generating economic value through eventual pharmaceutical product sales contingent on regulatory approval. Revenue is supplemented by substantial non-dilutive government funding, including a BARDA contract of up to $114.2 million for VE303 development and CARB-X grants of approximately $16.6 million. The company employs 101-250 staff, is privately held with institutional and strategic backers including Magnetar Capital, Pfizer, AMR Action Fund, and AXA Investment Managers, and is preparing commercial infrastructure under a newly appointed Head of Commercial.

Vedanta Biosciences firmographics

Firmographics
Name
Vedanta Biosciences
Legal name
Vedanta Biosciences, Inc.
Website
https://vedantabio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Vedanta Biosciences is a clinical-stage biopharmaceutical company developing orally administered defined bacterial consortia (Live Biotherapeutic Products) for serious gastrointestinal diseases, with lead asset VE303 in pivotal Phase 3 for recurrent C. difficile infection.
Ownership category
akta.pro rank

Vedanta Biosciences industry classification

Industry
Product category
Microbiome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYHLAAAFAC
Consortia & Defined Microbial Community Therapeutics
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)

Keywords

  • Microbiome therapeutics
  • Live biotherapeutic products
  • Bacterial consortia therapy
  • Gastrointestinal disease drugs
  • Biologics manufacturing

Where Vedanta Biosciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vedanta Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Developing Live Biotherapeutic Products (LBPs) for gastrointestinal diseases. VE303 is in Phase 3 registrational trial for prevention of recurrent C. difficile infection. Potential future revenue from pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Vedanta Biosciences product offering

Product offering

Core offering

Vedanta Biosciences develops and manufactures oral Live Biotherapeutic Products (LBPs) consisting of rationally designed defined bacterial consortia to treat gastrointestinal diseases. Its lead candidate VE303 is an eight-strain commensal bacterial consortium in pivotal Phase 3 development for the prevention of recurrent C. difficile infection. The company also develops VE202 for ulcerative colitis and VE707 for Gram-negative antimicrobial-resistant infections, supported by a proprietary product engine and in-house CGMP manufacturing.

Product overview

Vedanta Biosciences is developing a portfolio of defined bacterial consortia as oral Live Biotherapeutic Products (LBPs) for gastrointestinal diseases. The company's lead product is VE303, an eight-strain defined bacterial consortium in pivotal Phase 3 for prevention of recurrent C. difficile infection. VE202 (16-strain consortium for ulcerative colitis) completed Phase 2 but did not meet primary endpoint. VE707 is a preclinical program for Gram-negative AMR infections. The company's proprietary Product Engine platform enables rational selection and manufacturing of defined bacterial consortia from pure clonal cell banks, supported by in-house CGMP manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • VE303 VE303 is an orally-administered defined bacterial consortium candidate consisting of eight strains of live commensal bacteria developed for the prevention of recurrent C. difficile infection (rCDI). It is manufactured from pure clonal cell banks yielding a standardized pharmaceutical composition that bypasses the need for donor fecal material. VE303 is currently in pivotal Phase 3 (RESTORATiVE303) and holds FDA Orphan Drug and Fast Track designations.
  • VE202 VE202 is a defined bacterial consortium of 16 non-pathogenic, non-toxigenic Clostridia strains developed as an oral therapy for inflammatory bowel disease, specifically mild-to-moderate ulcerative colitis. The Phase 2 COLLECTiVE202 study did not meet its primary endpoint in August 2025.
  • VE707 VE707 is a preclinical defined bacterial consortium candidate designed to prevent Gram-negative antimicrobial-resistant (AMR) infections, including carbapenem-resistant and ESBL-producing Klebsiella pneumoniae and Escherichia coli, by reducing gut colonization with multidrug-resistant organisms in high-risk populations. IND submission is planned for 1H 2026.
  • Product Engine The Product Engine is Vedanta's proprietary discovery platform integrating one of the world's largest libraries of gut bacteria strains (nearly 100,000 isolates from hundreds of individuals across four continents), vast clinical datasets, proprietary computational consortium design tools, co-culture systems, and animal models. It supports rational selection and development of defined bacterial consortia as Live Biotherapeutic Products.

Quantifiable outcome

  • VE303 reduced CDI recurrence rate to 13.8% vs 45.5% for placebo (31.7% absolute risk reduction, >80% reduction in odds of recurrence) in Phase 2 CONSORTiUM study
  • +4 more outcomes

Companies that use Vedanta Biosciences

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Vedanta Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vedanta Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of TokyocoreStrategic or Co-development PartnerHonda patents are exclusively licensed to Vedanta from the University of Tokyo. These fundamental patents cover compositions and therapeutic uses of clostridial bacteria derived from the human microbiome. Dr. Kenya Honda, inventor, is a scientific co-founder of Vedanta.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Vedanta Biosciences competitors and assessment

Company assessment

Direct peers

  • Seres Therapeutics: Developed Vowst (SER-109), the first FDA-approved oral microbiome therapeutic for recurrent C. difficile infection. Directly comparable as a defined-consortium LBP competitor pursuing the same rCDI indication with an oral spore-based product.
  • Ferring Pharmaceuticals (Rebyota): Markets Rebyota (fecal microbiota, live-jslm), the first FDA-approved microbiome therapy for rCDI. Direct competitor in the recurrent CDI space, though Rebyota is rectally administered rather than oral.
  • Finch Therapeutics: Developed CP101, an oral microbiome therapeutic for recurrent C. difficile infection. Directly comparable microbiome platform pursuing the same rCDI indication, though Finch has scaled back operations.
  • Assembly Biosciences: Clinical-stage biotech developing microbiome-based therapies for serious diseases, including CDI and inflammatory conditions. Comparable as a platform LBP company with multiple defined-consortium programs.
  • MaaT Pharma: European clinical-stage company developing microbiome-based therapies (MaaT013, MaaT033) for GI diseases including CDI and acute Graft-versus-Host Disease. Direct microbiome peer operating in the same indication space.
  • Rebiotix (Ferring subsidiary): Pioneer in standardized FMT-based therapeutics, acquired by Ferring. Developed Rebyota, the first FDA-approved microbiome product, making it the closest historical comparator to Vedanta's LBP approach.
  • 4D pharma: UK-based clinical-stage microbiome therapeutics company developing single-strain and defined-consortium LBPs (e.g., Blautix for IBS). Comparable as a live biotherapeutic platform pursuing GI indications.

Emerging players

  • Second Genome: Clinical-stage biotech identifying microbiome-derived therapeutics for GI and metabolic diseases. Comparable microbiome discovery platform, though focused more on small-molecule drugs derived from microbiome insights than whole-consortium LBPs.
  • Eligo Bioscience: Developer of engineered phage-based microbiome medicines (Eligobiotics). Comparable as a microbiome-focused therapeutics platform, though uses a different modality (phage-delivered payloads rather than whole consortia).

Broad incumbents

  • Pfizer (CDI/AMR franchise): Major pharmaceutical investor in Vedanta with a broad infectious disease and CDI portfolio (historically Dificid). Comparable as a strategic counterparty and potential acquirer with overlapping interest in the rCDI market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Vedanta Biosciences social profiles

Digital presence

Vedanta Biosciences compliance and trust

Trust signal

Compliance2 records

Vedanta Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vedanta Biosciences leadership team

Management profile

Number of profiles

Profiles10 records

Vedanta Biosciences funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors43 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vedanta Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vedanta Biosciences

What does Vedanta Biosciences do?

Vedanta Biosciences develops and manufactures oral Live Biotherapeutic Products (LBPs) consisting of rationally designed defined bacterial consortia to treat gastrointestinal diseases. Its lead candidate VE303 is an eight-strain commensal bacterial consortium in pivotal Phase 3 development for the prevention of recurrent C. difficile infection. The company also develops VE202 for ulcerative colitis and VE707 for Gram-negative antimicrobial-resistant infections, supported by a proprietary product engine and in-house CGMP manufacturing.

Is Vedanta Biosciences a public or private company?

Vedanta Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vedanta Biosciences founded?

Vedanta Biosciences was founded in 2013. It employs 51 to 100 people.

Where is Vedanta Biosciences based?

Vedanta Biosciences is headquartered in Cambridge, United States, in the North America region.

How does Vedanta Biosciences make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Vedanta Biosciences's main competitors?

Direct peers on record are Seres Therapeutics, Ferring Pharmaceuticals (Rebyota), Finch Therapeutics, Assembly Biosciences, MaaT Pharma, Rebiotix (Ferring subsidiary) and 4D pharma. Emerging players are Second Genome and Eligo Bioscience. Pfizer (CDI/AMR franchise) is listed as a broad incumbent.

Does Vedanta Biosciences have an API?

No public API is recorded for Vedanta Biosciences.

What industry is Vedanta Biosciences in?

Vedanta Biosciences's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs), with a secondary code of HLAAAFAC, Consortia & Defined Microbial Community Therapeutics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooMicrobiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta BiosciencesThe global microbiome therapeutics market is projected to grow from USD 0.6 billion in 2026 to USD 4.6 billion by 2035, a CAGR of 25.4%. Growth is driven by clinical validation, regulatory approvals, and advances in microbiome science. Clinical programs are expanding into inflammatory bowel disease, oncology, and metabolic disorders.TechRoundBacteria, Billions and Buzzwords: Is the Gut Microbiome Startup Boom Backed by Science?Investors are backing companies that claim to decode the gut microbiome, with significant funds raised for both biotech firms and consumer health startups. Vedanta Biosciences leads with over $437 million, while ZOE has raised more than £118 million, demonstrating a split in investment between scientifically valid solutions and wellness products. The article discusses the ongoing debate about the scientific backing of these ventures amid a surge in consumer interest.VC News DailyVedanta Biosciences Nabs $60M Financing RoundVedanta Biosciences has secured $60 million in funding, comprising a $40 million financing round led by AMR Action Fund and BNP Paribas Asset Management Alts and an additional $20 million from BARDA. The proceeds will support the pivotal Phase 3 RESTORATiVE303 study of VE303 for preventing recurrent C. difficile infection, with topline efficacy data expected in the first half of 2027.pharmaphorumLifeMine gets $263m for transplant drug, and other financingsLifeMine Therapeutics raised $263 million in a dual financing to advance its transplant drug LIFE-001 into mid-stage trials. The company will start a phase 2 trial in kidney transplant patients and a phase 1b study in islet cell transplants. The financing is led by Milky Way Investments with new investors including Bezos Expeditions and Gates Frontier.VedantabioVedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 DataVedanta Biosciences secured $60 million in funding, including $40 million from existing investors and $20 million from BARDA, to support its Phase 3 RESTORATiVE303 study of VE303 for recurrent C. difficile infection. The trial has crossed 80% enrollment and expects topline data in 1H 2027. The company also appointed Manos Perros as Executive Chairman and Andrew Davis as independent Board Director.Pulse 2.0Vedanta Biosciences Raises $60 Million To Advance Phase 3 VE303 StudyVedanta Biosciences has raised $60 million in financing to advance its pivotal Phase 3 RESTORATiVE303 study of VE303 for preventing recurrent Clostridioides difficile infection, with $40 million from a funding round led by AMR Action Fund and BNP Paribas Asset Management Alts, and an additional $20 million through an existing BARDA contract. The trial has surpassed 80% enrollment across more than 150 sites in approximately 20 countries, with an independent Data Monitoring Committee recommending the study continue after the first interim analysis showed efficacy exceeding prespecified futility thresholds and no safety concerns. The company expects to complete enrollment in the second half of 2026 and report topline efficacy data in the first half of 2027, with plans to support a future Biologics License Application to the FDA.citybizVedanta Biosciences Raises $60 Million to Advance Phase 3 VE303 ProgramVedanta Biosciences secured $60 million in new financing to advance its Phase 3 VE303 program for preventing recurrent Clostridioides difficile infection, led by AMR Action Fund and BNP Paribas Asset Management Alts with additional support from BARDA. The Phase 3 RESTORATiVE303 trial has surpassed 80% enrollment across more than 150 clinical sites in approximately 20 countries, with topline efficacy data expected in the first half of 2027 to support a potential Biologics License Application with the FDA. The funding extends the company's runway through a critical value-creation milestone as it approaches a potential regulatory inflection point.Endpoints NewsVedanta gets $60M to finish Phase 3 for C. diff microbiome therapyVedanta Biosciences has secured $60 million in funding to advance its Clostridioides difficile (C. diff) microbiome therapy through Phase 3 clinical trials. The investment represents continued backing for one of the microbiome field's most established biotech companies as it approaches a Phase 3 readout. This funding milestone highlights ongoing investor interest in microbiome-based therapeutics for infectious disease applications.Venture Capital Access OnlineVedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 DataVedanta Biosciences secured $60 million in funding, including $40 million from existing investors and $20 million from BARDA, to support its Phase 3 RESTORATiVE303 study of VE303 for recurrent C. difficile infection. The trial has crossed 80% enrollment and expects topline data in 1H 2027. The company also appointed Manos Perros as Executive Chairman and Andrew Davis as independent Board Director.BioSpaceVedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 DataVedanta Biosciences secured $60 million in funding, including $40 million from existing investors and $20 million from BARDA, to support its Phase 3 RESTORATiVE303 study of VE303 for recurrent C. difficile infection. The trial has crossed 80% enrollment and expects topline data in 1H 2027. The company also appointed Manos Perros as Executive Chairman and Andrew Davis as independent Board Director.